Paclitaxel (Taxol)

Alastair J.J. Wood, Eric K. Rowinsky, Ross C. Donehower

Research output: Contribution to journalReview article

Abstract

The taxanes are an important new class of anticancer agents that exert their cytotoxic effects through a unique mechanism. Paclitaxel (Taxol), the first taxane in clinical trials, is active against a broad range of cancers that are generally considered to be refractory to conventional chemotherapy. This has led to the regulatory approval of paclitaxel in the United States and many other countries for use in the palliative therapy of patients with ovarian and breast cancers resistant to chemotherapy. The challenge now is to develop strategies using paclitaxel in the initial therapy of cancers in which cure or improved survival may.

Original languageEnglish (US)
Pages (from-to)1004-1014
Number of pages11
JournalNew England Journal of Medicine
Volume332
Issue number15
DOIs
StatePublished - Apr 13 1995

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Paclitaxel (Taxol)'. Together they form a unique fingerprint.

  • Cite this